- Investing Ideas
- /
- Danish Pharmaceuticals & Biotech High Growth Potential Companies
Danish Pharmaceuticals & Biotech High Growth Potential Companies
Results
6
Companies with a Future performance score of at least 3, ordered by Future performance score.
6 companies
Gubra
Market Cap: DKK 6.1b
A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.
GUBRA
DKK 377.00
7D
4.7%
1Y
32.7%
Novo Nordisk
Market Cap: DKK 1.9t
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
NOVO B
DKK 420.30
7D
-3.2%
1Y
-52.2%
ChemoMetec
Market Cap: DKK 8.0b
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.
CHEMM
DKK 458.20
7D
9.0%
1Y
50.7%
Genmab
Market Cap: DKK 77.7b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,225.00
7D
-0.7%
1Y
-40.5%
Zealand Pharma
Market Cap: DKK 30.2b
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
ZEAL
DKK 427.70
7D
4.2%
1Y
-28.1%
ALK-Abelló
Market Cap: DKK 31.1b
Operates as an allergy solutions company in Europe, North America, and internationally.
ALK B
DKK 140.60
7D
2.6%
1Y
9.3%